Vis enkel innførsel

dc.contributor.authorBech, Anne Berit
dc.contributor.authorClausen, Thomas
dc.contributor.authorWaal, Helge
dc.contributor.authorVindenes, Vigdis
dc.contributor.authorEdvardsen, Hilde Marie Erøy
dc.contributor.authorFrost, Joachim
dc.contributor.authorSkeie, Ivar
dc.coverage.spatialNorwayen_US
dc.date.accessioned2021-10-22T08:30:44Z
dc.date.available2021-10-22T08:30:44Z
dc.date.created2020-09-30T10:32:22Z
dc.date.issued2020
dc.identifier.citationBech, A. B., Clausen, T., Waal, H., Vindenes, V., Edvardsen, H. E., Frost, J., & Skeie, I. (2020). Post-mortem toxicological analyses of blood samples from 107 patients receiving opioid agonist treatment: substances detected and pooled opioid and benzodiazepine concentrations. Addiction (Abingdon, England), 10.1111/add.15211. Advance online publication. Https://doi.org/10.1111/add.15211en_US
dc.identifier.issn0965-2140
dc.identifier.urihttps://hdl.handle.net/11250/2824907
dc.description.abstractAbstract Aims: To present the substances and their concentrations detected post-mortem in patients receiving opioid agonist treatment (OAT) stratified by cause of death, estimate the pooled opioid and benzodiazepine concentrations using established conversion factors for blood concentrations from the Norwegian Road Traffic Act, and explore the association between drug-induced cause of death and the pooled opioid and benzodiazepine concentrations. Design: Cross-sectional nationwide study. Setting: Norway. Participants: One hundred and seven patients who died during OAT (i.e. within 5 days after the last intake of OAT medication) between 1 January 2014 and 31 December 2015, with post-mortem femoral blood available for toxicology. Data were collected from hospital records, the Norwegian Cause of Death Registry and autopsy reports. Measurements: Presence of alcohol and non-alcohol substances in the bloodstream at time of death, determined through records of toxicology of post-mortem femoral blood. Findings: A median of four substances was detected across the causes of death. At least one benzodiazepine was detected in 81 (76%) patients. The median pooled opioid concentration was significantly higher in drug-induced deaths compared with other causes of death (362 ng/mL versus 182 ng/mL, P < 0.001), in contrast to the pooled benzodiazepine concentration (5466 versus 5701 ng/mL, P = 0.353). The multivariate regression analysis showed that only increasing pooled opioid concentration (ng/ML) was associated with increased odds of a drug-induced cause of death (odds ratio, 1.003; 95% confidence interval: 1.001-1.006). Conclusions: In Norway, overall opioid concentration seems to play an important role in drug-induced deaths during opioid agonist treatment in patients prescribed methadone or buprenorphine. Patients prescribed buprenorphine tend to replace their agonist with full agonists, while patients prescribed methadone tend to have high opioid concentrations from methadone as the only opioid. This article is protected by copyright. All rights reserved.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsNavngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/deed.no*
dc.subjectAutopsy,en_US
dc.subjectbenzodiazepine,en_US
dc.subjectbuprenorphineen_US
dc.subjectdrugen_US
dc.subjectinduceden_US
dc.subjectforensicen_US
dc.subjectmethadoneen_US
dc.subjectopioid agonist treatmenten_US
dc.subjectoverdoseen_US
dc.subjectpolydrugen_US
dc.subjecttoxicologyen_US
dc.titlePostmortem toxicological analyses of blood samples from 107 patients receiving opioid agonist treatment: substances detected and pooled opioid and benzodiazepine concentrationsen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2020 The Authors. Article published by John Wiley & Sons Ltd. on behalf of Society for the Study of Addiction. This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproductionin any medium, provided the original work is properly cited and is not used for commercial purposes.en_US
dc.source.pagenumber11en_US
dc.source.journalAddictionen_US
dc.identifier.doi10.1111/add.15211
dc.identifier.cristin1835335
dc.relation.project[Hospital Innlandet Trust]: [150351]en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal